Supply of cephalexin (IBILEX 500) 500 mg capsules blister pack by Alphapharm Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply of therapeutic goods in Australia, ensuring that these products are of acceptable quality, safety and efficacy. One of the key objectives of the Act is to maintain public health and safety by controlling the importation, supply, and advertising of therapeutic goods. The Act was introduced to address the need for comprehensive regulation of therapeutic goods, which includes medicines, medical devices, and blood and blood components. The Act is administered by the Therapeutic Goods Administration (TGA), an agency of the Australian Government's Department of Health. The policy objective of the Act is to safeguard public health by ensuring that therapeutic goods available in Australia meet appropriate standards of quality, safety, and efficacy. The Act provides the legal framework for the regulation of therapeutic goods throughout their lifecycle, from research and development to post-market surveillance.

Scope and Application

The Therapeutic Goods Act 1989, specifically section 14 and 14A, pertains to the regulation of therapeutic goods in Australia, ensuring that these products meet required standards for safety, efficacy, and quality. This particular instance of the Act applies to Alphapharm Pty Ltd, a company engaged in the supply of therapeutic goods, specifically the product cephalexin (IBILEX 500) 500 mg capsules. The Act's jurisdictional reach is Commonwealth-wide, governing the supply of therapeutic goods across Australia. The consent given by the delegate of the Secretary under the Act is subject to certain conditions, including the limited application to specified batches of cephalexin products, and it extends to ensuring the batch number prefix is absent from the blister foil labels. This consent does not affect other batches or products and is limited to the batches identified in the notice. Additionally, a Dear Pharmacist letter must be supplied with the affected batches, advising on the circumstances and appropriate handling of these products. The Act's application can be further extended or restricted through subordinate instruments, ensuring flexibility in the regulation of therapeutic goods.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) governs the regulation of therapeutic goods in Australia. In particular, Section 14 and 14A provide mechanisms for the Minister to grant consents for the supply of therapeutic goods that do not comply with certain standards or specifications, subject to specified conditions. The Act allows the delegate of the Secretary of the Department of Health and Ageing to provide such consents under certain circumstances. In this instance, the delegate has given consent for the supply of the product cephalexin (IBILEX 500) 500 mg capsules blister pack by Alphapharm Pty Ltd, with specific conditions attached. The key provision of this legislation as it pertains to this consent is that the consent is limited to specific batches of the product, identified by their batch numbers. The consent is also subject to the condition that the foil labels for these batches must be identical to those submitted by the company, except for the absence of the batch number prefix, which is still present on the labels. The consent also requires that no other changes are made to the product, and that a Dear Pharmacist letter is supplied with the affected batches to inform pharmacists of the circumstances and provide instructions to patients. The obligations and requirements imposed by this legislation on the parties involved are relatively straightforward. The company, Alphapharm Pty Ltd, must ensure that the foil labels for the specified batches of the product are identical to those submitted to the delegate, except for the absence of the batch number prefix. They must also ensure that no other changes are made to the product, and that the Dear Pharmacist letter is supplied with the affected batches. The delegate, on their part, must ensure that the consent is granted subject to the specified conditions, and that any breaches of those conditions are addressed appropriately. The consequences of non-compliance with the provisions of the Act or the conditions of the consent are not explicitly stated in this particular instance. However, the Act generally provides for a range of civil and criminal penalties for breaches of its provisions, including fines and imprisonment. In addition, the delegate may revoke a consent if it is not being complied with, or if it appears that the consent is no longer necessary or appropriate. It is therefore important for parties subject to the Act to ensure that they comply with its provisions and any conditions attached to any consents granted under its authority. In summary, the Therapeutic Goods Act 1989 provides a framework for the regulation of therapeutic goods in Australia. Section 14 and 14A of the Act allow for the grant of consents for the supply of non-compliant products, subject to specified conditions. The consent granted in this instance applies to specific batches of the product cephalexin (IBILEX 500) 500 mg capsules blister pack, and requires that the foil labels for those batches are identical to those submitted by the company, except for the absence of the batch number prefix. The obligations and requirements imposed by the Act and the consent are relatively straightforward, and non-compliance may result in civil or criminal penalties or the revocation of the consent.